Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
Moodys
Mallinckrodt
Johnson and Johnson

Last Updated: November 28, 2021

DrugPatentWatch Database Preview

Suppliers and packages for generic ingredient: ELTROMBOPAG OLAMINE


Email this page to a colleague

« Back to Dashboard

ELTROMBOPAG OLAMINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant Tradename Generic Name Dosage NDA NDA/ANDA Supplier Package Code Package Marketing Start
Novartis PROMACTA KIT eltrombopag olamine FOR SUSPENSION;ORAL 207027 NDA Novartis Pharmaceuticals Corporation 0078-0697-61 1 CARTON in 1 KIT (0078-0697-61) > 30 PACKET in 1 CARTON (0078-0697-23) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0078-0697-19) 2018-09-27
Novartis PROMACTA KIT eltrombopag olamine FOR SUSPENSION;ORAL 207027 NDA Novartis Pharmaceuticals Corporation 0078-0972-61 1 CARTON in 1 KIT (0078-0972-61) > 30 PACKET in 1 CARTON (0078-0972-23) > 1 POWDER, FOR SUSPENSION in 1 PACKET (0078-0972-19) 2018-09-27
Novartis PROMACTA eltrombopag olamine TABLET;ORAL 022291 NDA Novartis Pharmaceuticals Corporation 0078-0684-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0684-15) 2016-08-22
Novartis PROMACTA eltrombopag olamine TABLET;ORAL 022291 NDA Novartis Pharmaceuticals Corporation 0078-0685-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0685-15) 2016-05-24
Novartis PROMACTA eltrombopag olamine TABLET;ORAL 022291 NDA Novartis Pharmaceuticals Corporation 0078-0686-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0686-15) 2016-04-07
Novartis PROMACTA eltrombopag olamine TABLET;ORAL 022291 NDA Novartis Pharmaceuticals Corporation 0078-0686-55 14 TABLET, FILM COATED in 1 BOTTLE (0078-0686-55) 2016-04-07
>Applicant >Tradename >Generic Name >Dosage >NDA >NDA/ANDA >Supplier >Package Code >Package >Marketing Start

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Express Scripts
Harvard Business School
Johnson and Johnson
AstraZeneca